Cutaneous leishmaniasis in a patient with psoriatic arthritis treated with tumour necrosis factor-α inhibitor

被引：0
|
作者：
Morsing, N., V [1 ]
Andreasen, C. M. [1 ]
Rasmussen, T. A. [2 ]
Moll, L. T. [1 ,3 ]
机构：
[1] Reg Hosp Godstrup, Dept Internal Med, Herning, Denmark
[2] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
[3] Dept Internal Med, Hosp parken 15, DK-7400 Herning, Denmark
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2024年 / 53卷 / 02期
关键词：
D O I：
10.1080/03009742.2023.2295627
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [1] Destructive cutaneous leishmaniasis in a patient being treated with anti-tumour necrosis factor-α
    Gurreri, R.
    Pistone, G.
    Bongiorno, M. R.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 113 - 113
  • [2] Scintigraphy for detecting tumour necrosis factor- on the skin of patients with psoriatic arthritis
    de Souza, S. A. L.
    Nentzinsky, V.
    do Carmo, C. C. M.
    Roimicher, L.
    da Fonseca, L. M. B.
    Gutfilen, B.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (05) : 377 - 380
  • [3] Severe glandular tularemia in a patient treated with anti-tumour necrosis factor for psoriatic arthritis
    Calin, Ruxandra
    Caumes, Eric
    Reibel, Florence
    Mohamed, Anzime Ali
    Brossier, Florence
    Foltz, Violaine
    Boussouar, Samia
    Fautrel, Bruno
    Maurin, Max
    Katlama, Christine
    Pourcher, Valerie
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 60 : 1 - 3
  • [4] Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis
    Stober, Carmel
    Ye, Weiyu
    Guruparan, Thushyanthan
    Htut, Eiphyu
    Clunie, Gavin
    Jadon, Deepak
    [J]. RHEUMATOLOGY, 2018, 57 (01) : 158 - 163
  • [5] Granulomatous interstitial nephritis treated with a tumour necrosis factor-α inhibitor
    Tomlinson, Laurie
    Davies, Kevin
    Wright, David A.
    Holt, Stephen
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (08) : 2311 - 2314
  • [6] Cutaneous leishmaniasis associated with anti-tumour necrosis factor-α drugs: an emerging disease
    Marcoval, J.
    Penin, R. M.
    Sabe, N.
    Valenti-Medina, F.
    Bonfill-Orti, M.
    Martinez-Molina, L.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2017, 42 (03) : 331 - 334
  • [7] Relapse of psoriatic arthritis in patients with active psoriasis switched from tumour necrosis factor-α to interleukin-17A inhibitor
    Gisondi, P.
    Geat, D.
    Idolazzi, L.
    Girolomoni, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) : 624 - 626
  • [8] Tumour necrosis factor-α polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis
    Al-Heresh, AM
    Proctor, J
    Jones, SM
    Dixey, J
    Cox, B
    Welsh, K
    McHugh, N
    [J]. RHEUMATOLOGY, 2002, 41 (05) : 525 - 530
  • [9] Interferon-γ- and tumour necrosis factor-α-producing cells in humans who are immune to cutaneous leishmaniasis
    Kemp, K
    Theander, TG
    Hviid, L
    Garfar, A
    Kharazmi, A
    Kemp, M
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1999, 49 (06) : 655 - 659
  • [10] Tumour necrosis factor inhibitor treatment in psoriatic arthritis: need for co-medication?
    Michelsen, B.
    Soldal, D.
    Kavanaugh, A.
    Boyle, D. L.
    Haugeberg, G.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 30 - 30
12345